Possible anti-tumor activity of initial treatment with zoledronic acid with hormonal therapy for bone-metastatic prostate cancer in multicenter clinical trial
International Journal of Clinical Oncology, 04/18/2012
Uemura H et al. – Simultaneous administration of zoledronic acid (ZOL) and maximal androgen blockade (MAB) as initial treatment delayed time to progression (TTP) in bone–metastatic prostate cancer patients. Initial treatment with ZOL has the possibility of anti–tumor activity to delay disease progression.